MetaCap

GH Research (GHRS) vs OPKO Health (OPK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GH Research (GHRS) has outperformed OPKO Health (OPK) over the past year, gaining 25.1% versus a gain of 18.9%. Over five years, GHRS leads with a -21.0% price change compared with -62.0% for OPK. GH Research is the larger company by market cap ($1.20 billion vs $1.17 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GHRS+25.08%OPK+18.94%
+125%+51%-23%
Nov 21, 20251 yearNov 20, 2026
GHRS-32.08%OPK-63.91%
+22%-31%-84%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GHRS versus OPK key metrics
MetricGHRSOPK
Share price$17.53$1.57
Market cap$1.20B$1.17B
1-day change-5.55%-2.48%
YTD return+38.03%+24.60%
1-year return+25.08%+18.94%
5-year return-21.00%-61.99%
EPS (TTM)$-0.94$-0.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$606.88M
Revenue growth (YoY)—-14.90%
Net income (latest FY)$-48.26M$-225.68M
Gross margin—33.93%
Operating margin—-19.35%
Net margin—-37.19%
52-week high$31.44$1.86
52-week low$12.04$0.98
Distance from 52-week high-44.24%-15.59%
Analyst consensusstrong_buybuy
Avg. price target upside+144.67%+164.33%
Average volume294.69K3.83M
Shares outstanding68.68M742.51M
Employees732,275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GH Research

GHRS stock →

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About OPKO Health

OPK stock →

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees

GHRS vs OPK FAQ

Which is bigger, GH Research or OPKO Health?

GH Research (GHRS) is larger, with a market capitalization of $1.20B compared with $1.17B for OPKO Health (OPK).

Which stock has performed better over the past year, GHRS or OPK?

GHRS returned +25.08% over the past 12 months, compared with +18.94% for OPK (price return, excluding dividends). Past performance does not predict future results.

Are GH Research and OPKO Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons